ArticleApplied microbiology and biotechnology2026
Multistep metabolic engineering of Pichia pastoris for biosynthesis of N‑acetylneuraminic acid.
Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic Engineering of Komagataella Phaffii for de Novo Synthesis of Retinol From Methanol.Biotechnology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Free or protein-conjugated N-Acetylneuraminic acid (Neu5Ac) is widely distributed in organisms and possesses diverse biological functions, and for example lactoferrin with Neu5Ac-mediated sialylation exhibits significantly enhanced functional activity compared with non-sialylated lactoferrin. Pichia pastoris serves as an excellent host for lactoferrin; however, efficient biosynthesis of Neu5Ac is essential for efficiently expressing lactoferrin with Neu5Ac-mediated sialylation. In this study, P. pastoris was engineered into a high-yield Neu5Ac host for expressing highly active lactoferrin with Neu5Ac modification. Heterologous Neu5Ac biosynthesis genes (gfa1, gna1, yqaB, age, and neuB) were first introduced into a P. pastoris strain in which pfk1 and zwf attenuation combined with pfk2 deletion redirected carbon flux toward fructose-6-phosphate, yielding the Neu5Ac-producing strain P. pastoris N1 with Neu5Ac production of 9.19 mg/L. Neu5Ac titers were subsequently boosted 2.8-fold via precursor enhancement through pyk attenuation and gs overexpression. Implementation of glucose-glycerol co-utilization (gut1, gut2, gt2 overexpression) dramatically increased Neu5Ac production to 285.41 mg/L. Optimization via increased copy number of gfa1, age, and neuB, coupled with their overexpression under the strong promoter P
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.